Sun Pharmaceutical Industries Limited ((IN:SUNPHARMA)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Sun Pharmaceutical Industries Limited has recently completed a significant clinical study titled ‘A Non-interventional, Multi-national, Multi-center Post-authorization Safety Study (PASS) to Assess the Long Term Safety and Tolerability of Odomzo (Sonidegib) Administered in Patients With Locally Advanced Cell Carcinoma (laBCC)’. The study aimed to collect real-world safety data on the use of sonidegib in adult patients with laBCC, focusing on major safety parameters such as treatment-related deaths, adverse events, and discontinuations due to adverse events.
The intervention being tested in this study is sonidegib, a drug administered orally at a dose of 200 mg once daily. This treatment is intended for patients with laBCC who are not suitable candidates for curative surgery or radiation therapy.
This observational study was designed with a cohort model and a prospective time perspective. It did not involve any allocation or masking, as it aimed to observe the natural use of sonidegib in clinical practice without imposing a specific treatment protocol.
The study began on March 11, 2019, and was completed with its last update submitted on June 23, 2025. These dates are crucial as they mark the timeline of the study’s execution and the availability of its findings.
The completion of this study could positively impact Sun Pharmaceutical’s stock performance and investor sentiment by providing valuable safety data that may enhance the market confidence in sonidegib. This update is particularly relevant in the competitive landscape of cancer treatments, where safety and efficacy are paramount.
The study is now completed, and further details can be accessed on the ClinicalTrials portal.